Australia's competition regulator opposes Australian Clinical Labs' offer to buy Healius
Dec 15 (Reuters) - Australia's competition regulator said on Friday it had decided to oppose the proposed acquisition of Healius Limited HLS.AX by Australian Clinical Labs. ACL.AX (Reporting by Archishma Iyer in Bengaluru; Editing by Shinjini Ganguli) ((Archishma.Iyer@thomsonreuters.com;))
Recent news on Australian Clinical Labs
See all newsBrief: Australian Clinical Labs Appoints Deloitte As Auditor
Australia's Optiscan rises after imaging more than 80 cases in ACL study
Australian Clinical Labs falls to over two-week low on trading ex-dividend
Australian Clinical Labs at 6-month high on upbeat full-year results, guidance
Brief: Australian Clinical Labs Says It Expects FY27 Revenue Of A$745-765 Million